Tadalafil (Generic) and Sildenafil Interaction: What You Need to Know

Tadalafil (generic Cialis, also marketed as Adcirca for pulmonary arterial hypertension) and sildenafil (Viagra, also marketed as Revatio for pulmonary arterial hypertension) are both phosphodiesterase-5 (PDE5) inhibitors. They are not interchangeable brand names for the same molecule; they are two distinct chemical entities in the same drug class, and that shared class membership is exactly why combining them is a problem.

The core, quotable answer: tadalafil and sildenafil act on the same target (PDE5), so co-administration produces additive vasodilation and additive blood-pressure lowering rather than additive erectile benefit. Current FDA-approved labeling for both drugs advises against use with another PDE5 inhibitor. This applies across the approved dose ranges for erectile dysfunction (tadalafil 2.5-20 mg; sildenafil 25-100 mg) and for the pulmonary arterial hypertension formulations (Adcirca, Revatio). No published evidence establishes a dose combination that is exempt from this concern.

Why combining them does not "double the effect" the way people assume

Erection and vascular smooth muscle relaxation both depend on cyclic guanosine monophosphate (cGMP). PDE5 breaks cGMP down. Blocking PDE5 lets cGMP accumulate, which relaxes smooth muscle, including in blood vessels outside the penis. Because tadalafil and sildenafil compete for the same enzyme site, using both does not add a second, independent mechanism of benefit. It intensifies the same mechanism, including its effect on systemic blood pressure.

This is the pharmacologic reason clinicians describe the combination as offering no meaningful efficacy advantage while adding risk. A patient who does not respond adequately to one PDE5 inhibitor is more appropriately managed by adjusting the dose of a single agent, switching agents with an adequate washout, or reassessing the underlying cause of erectile dysfunction, not by adding a second PDE5 inhibitor on top of the first.

Does a "low dose" of each drug make the combination safer?

No, based on how the interaction works. Pharmacodynamic interactions like this one are driven by how much of the PDE5 enzyme is occupied, not simply by the milligram number on the label. Tadalafil taken daily at 2.5 mg still maintains meaningful PDE5 occupancy across its roughly 17.5-hour half-life. Adding sildenafil, even at a modest dose, adds more occupancy on top of that baseline. The FDA labeling for tadalafil does not carve out an exception at low doses; it advises against combination with other PDE5 inhibitors generally. Anyone tempted to try a "low-low" combination should treat that as a decision to raise with a prescriber or pharmacist first, not a self-directed workaround.

What the FDA labeling actually establishes

The current FDA-approved prescribing information for tadalafil (Cialis) and for sildenafil (Viagra) each include language advising against combined use with other PDE5 inhibitors. This is the highest tier of evidence available for this question: a regulator-reviewed label position rather than an individual study. Readers and clinicians should confirm the exact current wording against the live label PDF, since labels are periodically revised and the version linked below reflects a specific historical revision date rather than a guarantee of the current text.

• Tadalafil (Cialis) label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021368s030lbl.pdf (2018 revision, verify current version before quoting)
• Sildenafil (Viagra) label: available on the FDA's drug label database (verify current version before quoting)

This article does not reproduce exact label sentences as direct quotations, because the precise phrasing should be checked against the live document before it is presented to a patient as a verbatim quote.

Pharmacokinetics: why the two drugs clear at different speeds

Tadalafil's longer half-life, roughly 17.5 hours in healthy adults with a published range often cited as 15 to 20 hours, is the reason it is dosed daily for benign prostatic hyperplasia and as-needed dosing still carries residual activity for days. Sildenafil's half-life is much shorter, commonly cited around 4 hours in healthy adults, longer in people over 65 or with hepatic impairment. Both drugs are cleared primarily through CYP3A4 metabolism.

Because five half-lives is a standard rule of thumb for considering a drug substantially cleared, tadalafil takes noticeably longer to wash out than sildenafil. The table below reflects commonly cited pharmacology figures. Exact hour cutoffs for a specific patient should be individualized by a prescriber or pharmacist, particularly for people with reduced kidney or liver function or those on interacting medications, and are not a substitute for personalized dosing guidance.

Who faces the highest risk from accidental combined exposure

Not every patient who accidentally takes both drugs faces the same danger. Groups that warrant particular caution include:

• People with known coronary artery disease, heart failure, or a prior heart attack, who tolerate blood pressure swings less well
• People taking an alpha-blocker such as tamsulosin or doxazosin, since alpha-blockers already lower blood pressure through a different vasodilatory pathway
• People with autonomic neuropathy (common in longstanding diabetes), whose reflexes cannot compensate as effectively for a sudden blood pressure drop
• Anyone taking an organic nitrate (nitroglycerin, isosorbide mononitrate or dinitrate), a combination both individual labels already treat as contraindicated on its own, independent of a second PDE5 inhibitor

What symptoms suggest a problem, and what to do

Additive PDE5 inhibition can produce flushing, headache, and lightheadedness on standing at the mild end, and syncope, chest pain, or loss of consciousness at the severe end. Mild symptoms still warrant sitting or lying down and contacting a clinician. Chest pain, fainting, or loss of consciousness after taking both drugs is a reason to call emergency services or go to an emergency department rather than wait it out at home.

There is no antidote for PDE5 inhibitor overexposure. Emergency management is supportive: positioning the patient supine, intravenous fluids for symptomatic hypotension, blood pressure and cardiac monitoring, and avoiding nitrates for as long as either drug could still be active. Vasopressor support may be needed in a hospital setting for refractory hypotension; that decision belongs to the treating clinical team, not to self-management.

Switching between the two drugs on purpose

Switching PDE5 inhibitors is a reasonable clinical decision when one drug is not working well or causes intolerable side effects. The distinction that matters is sequential use with an adequate gap, never concurrent use. A person on daily low-dose tadalafil for benign prostatic hyperplasia who wants to try sildenafil for erectile dysfunction should stop tadalafil and observe a washout period before the first sildenafil dose, with the exact duration set by a prescriber based on kidney and liver function and other medications. The reverse direction, from sildenafil to tadalafil, typically requires a shorter gap given sildenafil's shorter half-life, again to be confirmed with a prescriber.

Head-to-head efficacy differences between the two drugs at comparable approved doses are generally described in the literature as modest; side-effect profile and dosing convenience (daily versus as-needed) are usually the practical reasons a patient and prescriber choose one over the other, more than a large difference in effectiveness. A reader who wants the specific comparative trial data behind that statement should ask a pharmacist or prescriber to pull the current systematic review literature, since the exact study identifiers are not being reproduced here without direct verification.

CYP3A4 as a compounding factor

Neither tadalafil nor sildenafil meaningfully inhibits or induces CYP enzymes at approved doses, so the two drugs do not substantially change each other's blood levels through metabolism. The danger from combining them is pharmacodynamic (additive blood pressure effect), not pharmacokinetic. However, a separate concern arises when either drug is combined with a strong CYP3A4 inhibitor, such as ritonavir or ketoconazole. Those combinations can raise blood levels of tadalafil or sildenafil individually, and current FDA labeling addresses dose limits for sildenafil with ritonavir specifically. A patient on a strong CYP3A4 inhibitor who also has residual tadalafil or sildenafil in their system from a recent dose should have that combination reviewed by a pharmacist, since standard washout assumptions may not apply.

Evidence-status assessment: what is known, plausible, or unverified

Refer to this interaction table when discussing tadalafil use with your pharmacist or doctor, but always verify current prescribing information and consult clinical decision-support databases like Lexicomp or Micromedex for the most up-to-date guidance.

Practical counseling points

• Tell every prescriber about every PDE5 inhibitor you take, including a daily low dose prescribed for prostate symptoms rather than erectile dysfunction.
• Do not add an over-the-counter or online sildenafil purchase on top of an existing tadalafil prescription without telling the prescribing clinician.
• Alcohol adds its own vasodilatory effect and should be avoided if accidental combined exposure has occurred.
• If you believe you have taken both drugs within the same day, sit or lie down, avoid standing up quickly, and seek urgent care for chest pain, fainting, or severe lightheadedness.

What this article does not establish

This article does not provide individualized dosing or switching instructions for any specific patient's kidney function, liver function, cardiac history, or full medication list. It does not confirm the exact current text of either FDA label at the moment you are reading this, since labels change over time. Numeric figures describing percentage increases in drug exposure, exact hour-based washout cutoffs, and any adverse-event counts should be verified against the current FDA label and a pharmacist or prescriber before being used to make a clinical decision.